G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial

BLOOD CANCER JOURNAL

SPRINGERNATURE

1. Ministry of Health (AZV) [NU21-08-00312, NU22-05-00374]
2. EXCELES (National Institute for Cancer Research) [LX22NPO5102]
3. Charles University [UNCE/MED/016, ProgresQ26, SVV260521]
4. General Hospital Fund [RVO-VFN-64165]
5. [GAR 21-13323S]